US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

640.36

-28.0263-4.19%

Number of Gainers:44

Number of Losers:110

Number of Flat:13

PE:- -

High:668.38

Open:668.38

Low:634.70

Close:668.38

Volume:325.06M

Turnover:10.94B

Market Cap:480.25B

Float Cap:346.21B

Loading ...

Absci Corp - Launches Endometriosis Advisory Board for Abs-201 Program

THOMSON REUTERS

Turn Therapeutics secures up to $25M in financing

Intensity Therapeutics issued new patent in the US

LENZ Therapeutics Q4 net loss widens on VIZZ launch costs

LENZ Q4 net loss rises 184% to USD 35.9 million, SG&A expenses jump 323% to USD 40 million

Absci launches ABS-201 endometriosis advisory board

Lenz Therapeutics Inc - Q4 2025 Product Revenue Approx $1.6 Mln

THOMSON REUTERS

Lenz Therapeutics Q4 Net Income USD -35.896 Million

THOMSON REUTERS

Lenz Therapeutics Q4 Income From Operations USD -38.463 Million

THOMSON REUTERS

Lenz Therapeutics Q4 Operating Expenses USD 40.051 Million

THOMSON REUTERS

Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Press Release: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Core & Main down 6% after Q4 results and guidance

Ethereum price near $2,150 as buy zone call returns

Core & Main's Q4 sales miss expectations on lower volumes

Core & Main Q4 fiscal 2025 net income rose 9% to USD 73 million on net sales down 6.9% to USD 1,581 million

UTime files initial beneficial ownership statement for Chief Manufacturing Officer Cao Honggang

BRIEF-Core & Main Q4 Sales USD 1,581 Million Vs. IBES Estimate USD 1,599 Million

Core & Main Q4 Sales USD 1,581 Million VS. Ibes Estimate USD 1,599 Million

THOMSON REUTERS

Core & Main Outlook FY Net Sales of $7,800 Mln to $7,900 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4539/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":640.35693,"timestamp":1774382399999,"preClose":668.38324,"halted":0,"volume":325057217,"delay":0,"changeRate":-0.041931,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-28.026306,"latestTime":"03-24 16:00:00 EDT","open":668.3818,"high":668.3818,"low":634.69696,"amount":10939033207.88615,"amplitude":0.050397,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.376015,"peRate":176.12387,"turnoverRate":0.023111,"increases":44,"decrements":110,"flats":8,"marketCap":480253958362.125,"floatMarketCap":346212292848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":668.3818,"amplitude":0.050397,"preClose":668.38324,"low":634.69696,"pbRate":"5.376015","latestPrice":640.35693,"volume":325057217,"delay":0,"open":668.3818,"prevYearClose":881.5255,"prevWeekClose":652.8748,"prevMonthClose":663.4647,"prevQuarterClose":881.5255,"fiveDayClose":684.654,"twentyDayClose":633.0492,"sixtyDayClose":928.8742,"secType":"PLATE","market":"US","turnoverRate":0.023111,"peRate":176.12387,"marketCap":480253958362.125,"floatMarketCap":346212292848,"timestamp":1774382399999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":44,"down":110,"flat":13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621640220","title":"Absci Corp - Launches Endometriosis Advisory Board for Abs-201 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2621640220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621640220?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:23","pubTimestamp":1774354990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABSI","BK4121","BK4139","BK4539"],"gpt_icon":0},{"id":"2621640870","title":"Turn Therapeutics secures up to $25M in financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621640870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621640870?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:12","pubTimestamp":1774354379,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) entered into a growth capital loan facility with Avenue Venture Opportunities Fund II for up to $25M. The facility include...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-secures-up-to-25m-in-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-secures-up-to-25m-in-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","TTRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2621640330","title":"Intensity Therapeutics issued new patent in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2621640330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621640330?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:12","pubTimestamp":1774354363,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) provided an update on its patent portfolio including the recent issuance in December 2025 of a new patent in the U.S....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ","INTS"],"gpt_icon":0},{"id":"2621123064","title":"LENZ Therapeutics Q4 net loss widens on VIZZ launch costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621123064","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621123064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:11","pubTimestamp":1774354310,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics Q4 net loss widens on VIZZ launch costsOverviewUS pharmaceutical company's Q4 2025 product revenue reached $1.6 mln after VIZZ launchNet loss for Q4 2025 widened to $35.9 mln, reflec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL1N40C0IQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2621064669","title":"LENZ Q4 net loss rises 184% to USD 35.9 million, SG&A expenses jump 323% to USD 40 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064669?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353874,"startTime":"0","endTime":"0","summary":"Lenz published a press release reporting fourth-quarter and full-year 2025 financial results and recent corporate highlights.Q4 product sales, net were USD 1.6 million, while net loss was USD 35.9 million, or USD 1.16 per share.Full-year total revenue was USD 19.09 million, including USD 17.5 million of license revenue and USD 1.6 million of product sales, net.FY SG&A expenses rose to USD 91.1 million and FY R&D expenses fell to USD 18.7 million, reflecting commercial launch buildout and the conclusion of the Phase 3 CLARITY study and subsequent FDA approval of VIZZ.Cash, cash equivalents and marketable securities totaled USD 292.3 million, and management said this is expected to fund operations to post-launch positive operating cash flow.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6NHY58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2621064346","title":"Absci launches ABS-201 endometriosis advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064346?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:01","pubTimestamp":1774353671,"startTime":"0","endTime":"0","summary":"Absci announced the ABS-201 program for endometriosis and launched an external advisory board to support clinical strategy and study design.The program targets a large unmet-need market, with endometriosis affecting an estimated 190 million people worldwide.ABS-201 is positioned as a non-hormonal approach, which could differentiate it from current treatments that rely on hormonal suppression.The company said it anticipates initiating a Phase 2 study in Q4 2026, with an interim data readout expected in the second half of 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7hv80h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","LU2210150020.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","NDAQ","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4539","LU0314104364.USD","LU2210149790.SGD","BK4121","IE00BKPKM429.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BGHQF748.EUR","BK4112","BK4585","BK4139"],"gpt_icon":0},{"id":"2621657064","title":"Lenz Therapeutics Inc - Q4 2025 Product Revenue Approx $1.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621657064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621657064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA4J7JW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2621838064","title":"Lenz Therapeutics Q4 Net Income USD -35.896 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621838064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621838064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2621064895","title":"Lenz Therapeutics Q4 Income From Operations USD -38.463 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064895?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2621061716","title":"Lenz Therapeutics Q4 Operating Expenses USD 40.051 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061716?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2621384064","title":"Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621384064","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621384064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353600,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., March 24, 2026  -- Mineralys Therapeutics, Inc. , a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer.\"Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,\" said Jon Congleton, Chief Executive Officer of Mineralys. \"His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.\". Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","MLYS","LENZ","BK4539"],"gpt_icon":0},{"id":"2621061010","title":"Press Release: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061010","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353600,"startTime":"0","endTime":"0","summary":"Launched VIZZ  1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch. On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals. Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category. \"We are encouraged by the early performance of VIZZ. We undoubtedly have a product that works, with broad prescriber uptake and early signs of encouraging refill dynamics reinforcing its best-in-class profile,\" said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. \"We are clearly establishing a new category, with physicians building new habits of identifying appropriate patients and incorporating VIZZ into routine discussions. To accelerate this, we are l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4081","BK4585","BK4139","EMA","BK4232","R","BK4215","BK4007","LENZ","MAA","BK4022","BK4539"],"gpt_icon":0},{"id":"2621648760","title":"Core & Main down 6% after Q4 results and guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2621648760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621648760?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353057,"startTime":"0","endTime":"0","summary":"07:45 EDT Core & Main down 6% after Q4 results and guidance Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/core-main-down-6-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/core-main-down-6-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNM","IE0009354923.USD","BK4539","LU1923621640.USD","LU2125910179.SGD","LU2125910336.SGD","LU2089279066.USD","LU2229751404.USD","BK4104"],"gpt_icon":0},{"id":"2621612650","title":"Ethereum price near $2,150 as buy zone call returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2621612650","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621612650?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:45","pubTimestamp":1774352759,"startTime":"0","endTime":"0","summary":"Ethereum  has returned to focus after new market data pointed to a possible bullish setup. Analysts are tracking valuation metrics, treasury buying, and exchange flows as ETH tries to build on its recent rebound.Ethereum price entered a buy zone after MVRV fell below 0.8, matching past cycle bottom signals.Bitmine bought $140 million in ETH this week, raising holdings toward its 5% supply target.Coinbase premium stayed negative, showing weaker U.S. demand even as Ethereum posted a sharp rebound.The latest discussion centers on Ethereum’s Market Value to Realized Value ratio, or MVRV, which has moved below 0.8. At the same time, Bitmine has expanded its Ethereum holdings, while Coinbase premium data has shown weaker demand from U.S. buyers.Crypto analyst Ali Martinez said Ethereum may have entered a “generational buy zone” after the MVRV ratio dropped below 0.8. He linked that reading to earlier market bottoms that later led to strong recoveries.A negative premium often signals weaker a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/ethereum-price-near-2150-as-buy-zone-call-returns/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/ethereum-price-near-2150-as-buy-zone-call-returns/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["COIO","FIAT","CONI","COII","LU1861559042.SGD","ICOI","COIA","CONX","CONY","BK4539","ETHW","ETU","BTF","SETH","COYY","BK4596","ETH.USD.CC","LU2360107671.USD","BK4588","ETQ","LU1861220207.SGD","LU1861217088.USD","BK4535","ETH","BK4551","BK4516","BK1611","BK4601","LU1861558580.USD","BK4585","BK4112","COIW","ETCO","BK4595","ETHI","BK4554","BK4600","YETH","COIG"],"gpt_icon":1},{"id":"2621061508","title":"Core & Main's Q4 sales miss expectations on lower volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061508","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061508?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:40","pubTimestamp":1774352448,"startTime":"0","endTime":"0","summary":"Core & Main's Q4 sales miss expectations on lower volumesOverviewUS water infrastructure distributor's fiscal Q4 sales declined 6.9%, missing analyst expectationsAdjusted EPS for fiscal Q4 beat analys","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL1N40C0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNM","IE0009354923.USD","LU2125910336.SGD","LU2125910179.SGD","LU2229751404.USD","LU2089279066.USD","LU1923621640.USD","BK4104","BK4539"],"gpt_icon":0},{"id":"2621069007","title":"Core & Main Q4 fiscal 2025 net income rose 9% to USD 73 million on net sales down 6.9% to USD 1,581 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069007?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:32","pubTimestamp":1774351950,"startTime":"0","endTime":"0","summary":"Core & Main published a press release reporting fourth-quarter and full-year results, with Q4 net sales down 6.9% to USD 1.6 billion and gross margin up 50 basis points to 27.1%.Q4 net income rose 9% to USD 73 million and diluted EPS increased 12.1% to USD 0.37, with the net income increase attributed to lower interest expense and higher other income, partly offset by lower operating income.For the full year, net sales increased 2.8% to USD 7.6 billion and net income rose 6.5% to USD 462 million, with the sales increase driven by higher average daily net sales from higher volumes and acquisitions, partly offset by one less selling week.Full-year adjusted EBITDA increased 0.1% to USD 931 million and operating cash flow was USD 650 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9wYNlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","LU1923621640.USD","LU2125910336.SGD","LU2229751404.USD","LU2125910179.SGD","LU2089279066.USD","BK4539","IE0009354923.USD","CNM"],"gpt_icon":0},{"id":"2621061889","title":"UTime files initial beneficial ownership statement for Chief Manufacturing Officer Cao Honggang","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061889","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:32","pubTimestamp":1774351943,"startTime":"0","endTime":"0","summary":"UTime reported an initial Form 3 filing by Honggang Cao, its chief manufacturing officer, with the event date listed as March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UTime Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDLbYxRvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4145","BK4539","WTO"],"gpt_icon":0},{"id":"2621069004","title":"BRIEF-Core & Main Q4 Sales USD 1,581 Million Vs. IBES Estimate USD 1,599 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069004","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069004?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351846,"startTime":"0","endTime":"0","summary":"BRIEF-Core & Main Q4 Sales USD 1,581 Million Vs. IBES Estimate USD 1,599 Million\n\n\nMar 24 (Reuters) - Core & Main Q4 adjusted EPS USD 0.52 vs. IBES estimate USD 0.42.\n\nQ4 net income USD 73 million\nQ4 adjusted EBITDA USD 167 million vs. IBES estimate USD 166.1 million\nQ4 EPS USD 0.37","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXF99234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LU2089279066.USD","LU2125910336.SGD","LU1923621640.USD","LU2125910179.SGD","CNM","LU2229751404.USD","BK4104","BK4539"],"gpt_icon":0},{"id":"2621069241","title":"Core & Main Q4 Sales USD 1,581 Million VS. Ibes Estimate USD 1,599 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069241","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069241?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXF99234:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2125910179.SGD","LU2089279066.USD","BK4539","CNM","LU1923621640.USD","BK4104","IE0009354923.USD","LU2229751404.USD","LU2125910336.SGD"],"gpt_icon":0},{"id":"2621061360","title":"Core & Main Outlook FY Net Sales of $7,800 Mln to $7,900 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061360?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXF99234:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNM","LU2125910179.SGD","LU2089279066.USD","BK4539","LU2229751404.USD","LU2125910336.SGD","BK4104","LU1923621640.USD","IE0009354923.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":74,"pageCount":6,"totalSize":1478,"code":"91000000","status":"200"}]}}